All In Biotech

Drug Trial Radar · NCT05393271

First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4011499 in Healthy Participants

A Randomized, Double-Blind (Sponsor Unblinded), Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Orally Administered VH4011499 in Healthy Participants

Last checked: Nov 20, 2026Latest source record: Apr 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

73

Actual

Start

Oct 3, 2022

Primary completion

Apr 24, 2023

Study completion Apr 24, 2023

Sponsor

Lead sponsor
ViiV HealthcareGSK (GSK)
Sponsor type
Industry
First posted
May 26, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This FTIH study aims to evaluate the safety, tolerability and PK of the novel investigational Human immunodeficiency virus (HIV)-1 capsid inhibitor VH4011499 in healthy adults. The study will be conducted in 3 parts: Part 1 will investigate single ascending doses (SAD) and Part 2 will investigate multiple ascending doses (MAD). Part 3 will investigate single dose of a new formulation of VH4011499. The transition from SAD to MAD will be based on the assessment of the Safety and Dose Escalation Committee.

Conditions

  • HIV Infections

Interventions

  • VH4011499Drug

    VH4011499 will be administered.

  • PlaceboDrug

    Placebo will be administered.

  • MidazolamDrug

    Midazolam will be administered

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Number of Participants With Adverse Events (AEs)Time frame: Up to Day 28
  2. Part 2: Number of Participants With AEsTime frame: Up to Day 42
  3. Part 3: Number of Participants With AEsTime frame: Up to Day 28
  4. Part 1: Number of Participants With AEs by SeverityTime frame: Up to Day 28
  5. Part 2: Number of Participants With AEs by SeverityTime frame: Up to Day 42
  6. Part 3: Number of Participants With AEs by SeverityTime frame: Up to Day 28
  7. Part 2: Number of Participants Discontinuing Treatment Due to AEsTime frame: Up to Day 42
  8. Part 1: Absolute Values of Liver Panel Parameters: Direct Bilirubin, Total BilirubinTime frame: Up to Day 28
  9. Part 1: Absolute Values of Liver Panel Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP) and Aspartate Aminotransferase (AST)Time frame: Up to Day 28
  10. Part 2: Absolute Values of Liver Panel Parameters: Direct Bilirubin, Total BilirubinTime frame: Up to Day 42
  11. Part 2: Absolute Values of Liver Panel Parameters: ALT, ALP and ASTTime frame: Up to Day 42
  12. Part 3: Absolute Values of Liver Panel Parameters: Direct Bilirubin, Total BilirubinTime frame: Up to Day 28
  13. Part 3: Absolute Values of Liver Panel Parameters: ALT, ALP and ASTTime frame: Up to Day 28
  14. Part 1: Change From Baseline in Liver Panel Parameters: Direct Bilirubin, Total BilirubinTime frame: From Baseline (Day 1) and up to Day 28
  15. Part 1: Change From Baseline in Liver Panel Parameters: ALT, ALP and ASTTime frame: From Baseline (Day 1) and up to Day 28
  16. Part 2: Change From Baseline in Liver Panel Parameters: Direct Bilirubin, Total BilirubinTime frame: From Baseline (Day 1) and up to Day 42
  17. Part 2: Change From Baseline in Liver Panel Parameters: ALT, ALP and ASTTime frame: From Baseline (Day 1) and up to Day 42
  18. Part 3: Change From Baseline in Liver Panel Parameters: Direct Bilirubin, Total BilirubinTime frame: From Baseline (Day 1) and up to Day 28
  19. Part 3: Change From Baseline in Liver Panel Parameters: ALT, ALP and ASTTime frame: From Baseline (Day 1) and up to Day 28
  20. Part 1: Number of Participants With Maximum Toxicity Grade Increase From Baseline for Liver Panel ParametersTime frame: Up to Day 28
  21. Part 2: Number of Participants With Maximum Toxicity Grade Increase From Baseline for Liver Panel ParametersTime frame: Up to Day 42
  22. Part 3: Number of Participants With Maximum Toxicity Grade Increase From Baseline for Liver Panel ParametersTime frame: Up to Day 28
  23. Part 1: Area Under the Plasma Concentration Time Curve (AUC) From Time Zero to Infinity (0-inf) Following Single Dose Administration of VH4011499Time frame: At Day 1
  24. Part 2: AUC Over a Dosing Interval From Time of Dosing to the Time of the Subsequent Dose (0-t) Following Repeat Dose Administration of VH4011499Time frame: At Days 1 and 14 for Part 2 (MAD): VH4011499 200 mg PiB and Part 2 (MAD): VH4011499 400 mg PiB groups, and at Days 2 and 15 for Part 2 (MAD): VH4011499 300 mg + Midazolam PiB group
  25. Part 1: Maximum Observed Plasma Concentration (Cmax) Following Single Dose Administration of VH4011499.Time frame: At Day 1
  26. Part 1: Time to Maximum Observed Plasma Concentration (Tmax) Following Single Dose Administration of VH4011499Time frame: At Day 1
  27. Part 1: Apparent Terminal Half-life (T1/2) Following Single Dose Administration of VH4011499Time frame: At Day 1
  28. Part 2: Cmax Following Repeat Dose Administration of VH4011499Time frame: At Days 1 and 14 for Part 2 (MAD): VH4011499 200 mg PiB and Part 2 (MAD): VH4011499 400 mg PiB groups, and at Days 2 and 15 for Part 2 (MAD): VH4011499 300 mg + Midazolam PiB group
  29. Part 2: Tmax Following Repeat Dose Administration of VH4011499Time frame: At Days 1 and 14 for Part 2 (MAD): VH4011499 200 mg PiB and Part 2 (MAD): VH4011499 400 mg PiB groups, and at Days 2 and 15 for Part 2 (MAD): VH4011499 300 mg + Midazolam PiB group
  30. Part 2: T1/2 Following Repeat Dose Administration of VH4011499Time frame: At Day 14 for Part 2 (MAD): VH4011499 200 mg PiB and Part 2 (MAD): VH4011499 400 mg PiB groups, and at Day 15 for Part 2 (MAD): VH4011499 300 mg + Midazolam PiB group

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Las Vegas, Nevada

  • GSK Investigational Site

    Austin, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.